TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24029022

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided combined sciatic-femoral nerve block (USFB) with a 25 ml mixture (10 ml of 2.0% lidocaine, 10 ml of 0.5% levobupivacaine, and 5 ml of saline)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unilateral spinal anaesthesia (USA) with 2 ml (10 mg) of 0.5% levobupivacaine
Number of subjects: 40
Study: 22052141

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 39
Study: 19349078

Group type: EXPERIMENTAL
Intervention: Clomipramine (mean dose 125 mg daily)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 16700824

Group type: EXPERIMENTAL
Intervention: Valproic acid (27.9±14.8 mg/kg/24 hr)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 30
Study: 15063241

Group type: EXPERIMENTAL
Intervention: Holmium:yttrium‐aluminum‐garnet TMR (n = 100)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Continued medical management (n = 112)
Number of subjects: 212
Study: 11056853

Group type: EXPERIMENTAL
Intervention: Initial hemoglobin level (Hb) < median (13.5 g/dl)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Total tumor volume (TTV) > median (98 ml)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Severe anemia (Hb < 10 g/dl)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Tumor oxygenation
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Other parameters examined
Number of subjects: 125
Study: 9067045

Group type: EXPERIMENTAL
Intervention: Oral clonidine 5 micrograms.kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 8384388

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin) 5,000 IU subcutaneously once daily for six days, starting preoperatively
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 3529801

Group type: EXPERIMENTAL
Intervention: 3 hours exposure to humidified nitrogen gas (anoxia)
Number of subjects: 9
Study: 30290627

Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Air‐Q
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: I‐Gel
Number of subjects: 134
Study: 27128496

Group type: EXPERIMENTAL
Intervention: Oxycodone (1 mg/mL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fentanyl (15 μg/mL)
Number of subjects: 82
Study: 24738793

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NBUVB) plus methotrexate (MTX)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Narrowband ultraviolet B (NBUVB) alone
Number of subjects: 113

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 113
Study: 22762290

Group type: EXPERIMENTAL
Intervention: Pancreatin (Creon 40000 MMS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 20558909

Group type: EXPERIMENTAL
Intervention: efonidipine 20-60 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: amlodipine 2.5-7.5 mg once daily
Number of subjects: 20
Study: 18459154

Group type: EXPERIMENTAL
Intervention: 41 degrees C footbath for 40 minutes before sleep onset
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no footbath)
Number of subjects: 15
Study: 16024209

Group type: EXPERIMENTAL
Intervention: Trained counselors
Number of subjects: 158

Group type: COMPARATOR
Intervention: Untrained counselors
Number of subjects: 158
Study: 12884545

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 mg daily in pellets for 8 to 12 hours)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no vitamin C supplementation)
Number of subjects: 76
Study: 10871560

Group type: EXPERIMENTAL
Intervention: 20 g oat bran concentrate (OBC; containing 3 g beta-glucan)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 20 g wheat bran (control)
Number of subjects: 62
Study: 9192129

Group type: EXPERIMENTAL
Intervention: Aerobics training (20-25 minutes, three times a week for eight weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cycle ergometer training (20 minutes at 160-170 beats/minute, three times a week for eight weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 51
Study: 1555902

Group type: EXPERIMENTAL
Intervention: Category Ratio Scale (CR-10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Magnitude Estimation (ME)
Number of subjects: 24
Study: 3878659

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) at 2 Hz
Number of subjects: 12

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) at 100 Hz
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vibration at 100 Hz
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: All types of conditioning stimulation
Number of subjects: 12
Study: 30399092

Group type: EXPERIMENTAL
Intervention: Serial ultrasound examinations every 4 weeks
Number of subjects: 206

Group type: COMPARATOR
Intervention: Routine care (control arm)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Serial ultrasound examinations
Number of subjects: 206
Study: 26211415

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard social support (SS)
Number of subjects: 38
Study: 25237186

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 22321402

Group type: EXPERIMENTAL
Intervention: Three-curved rocker sole shoe
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 8
Study: 19625274

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study: 18846777

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg (single dose)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nifedipine (12 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day (for one week)
Number of subjects: 55
Study: 16422308

Group type: EXPERIMENTAL
Intervention: Standard group sequential methods
Number of subjects: 0
Study: 14750352

Group type: EXPERIMENTAL
Intervention: Rapid Rhino Goodman pack
Number of subjects: 14

Group type: COMPARATOR
Intervention: Merocel pack
Number of subjects: 14
Study: 10353573

Group type: EXPERIMENTAL
Intervention: Generic beclomethasone 42 microg
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Generic beclomethasone 84 microg
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Generic beclomethasone 42 microg and 84 microg
Number of subjects: 518

Group type: COMPARATOR
Intervention: Generic beclomethasone
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Generic beclomethasone and innovator beclomethasone
Number of subjects: 518
Study: 7555212

Group type: EXPERIMENTAL
Intervention: Ceftazidime (group CAZ)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Best guess combined antibiotic therapy (group COMB)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Open group with free combination of antibiotics (group OPEN)
Number of subjects: 128
Study: 1934434

Group type: EXPERIMENTAL
Intervention: Low hemoglobin low flow warm blood cardioplegia (50 g/l, <80 ml/min)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: High hemoglobin high flow warm blood cardioplegia (80 g/l, >80 ml/min)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intermittent cold blood cardioplegia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Continuous normothermic cardioplegia (80 ml/min or greater, 80 g/l)
Number of subjects: 35
Study: 7072624

Group type: EXPERIMENTAL
Intervention: 60 mg iron once daily
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: 60 mg iron 3 times daily
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: 60 mg iron 3 times daily plus a 5‐mg folic acid tablet once daily
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: 60 mg iron 3 times daily plus a 5‐mg folic acid tablet once daily and weekly antimalarial prophylactic
Number of subjects: 621

Group type: COMPARATOR
Intervention: Untreated women (control group)
Number of subjects: 621
Study: 31917731

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg every 4 weeks (2q4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravitreal aflibercept 2 mg every 12 weeks (2q12)
Number of subjects: 40
Study: 30896648

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval (HII) exercise for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (medications without exercise)
Number of subjects: 32
Study: 28495347

Group type: EXPERIMENTAL
Intervention: Sinedie clinical decision support system
Number of subjects: 90
Study: 26866933

Group type: EXPERIMENTAL
Intervention: Transanal submucosal injection of polyacrylamide hydrogel
Number of subjects: 30
Study: 24717710

Group type: EXPERIMENTAL
Intervention: DentalVibe Injection Comfort System
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional injection without the aid of the DentalVibe
Number of subjects: 36
Study: 21938381

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18608553

Group type: EXPERIMENTAL
Intervention: β‐lactoglobulin‐enriched WPI
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: WPI
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All protein drinks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hydrolysed WPI
Number of subjects: 8

Group type: COMPARATOR
Intervention: Flavour‐identical control
Number of subjects: 8
Study: 17499695

Group type: EXPERIMENTAL
Intervention: Dynamic transcricothyroid ultrasonography (US)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Static transcricothyroid ultrasonography (US)
Number of subjects: 7
Study: 15202930

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nitric oxide donor and sodium nitroprusside (control)
Number of subjects: 20
Study: 11772772

Group type: EXPERIMENTAL
Intervention: STD/HIV behavior change intervention
Number of subjects: 604
Study: 9693241

Group type: EXPERIMENTAL
Intervention: Piritramide (0.1‐0.3 mg/kg) and midazolam (1‐3 mg) i.v.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream (30 g) topically and diclofenac suppository (100 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 95
Study: 7662079

Group type: EXPERIMENTAL
Intervention: Cefcanel 300 mg tablets twice daily
Number of subjects: 354

Group type: COMPARATOR
Intervention: Cefaclor 250 mg capsules three times daily
Number of subjects: 354
Study: 2547256

Group type: EXPERIMENTAL
Intervention: Prophylactic anti-CMV immunoglobulin administration
Number of subjects: 39
Study: 325837

Group type: EXPERIMENTAL
Intervention: IR regimen (isoniazid and rifampicin for 3 months followed by isoniazid and either streptomycin or ethambutol for 6 months)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: ISE regimen (isoniazid, streptomycin and ethambutol for 3 months followed by isoniazid and either streptomycin or ethambutol for 6 months)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 232
Study: 31805854

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 35
Study: 27669664

Group type: EXPERIMENTAL
Intervention: Chewed oxycodone DETERx
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intact oxycodone DETERx
Number of subjects: 38

Group type: COMPARATOR
Intervention: Crushed immediate-release oxycodone
Number of subjects: 38
Study: 25698069

Group type: EXPERIMENTAL
Intervention: Verbal information condition
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Approach‐avoidance training
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined condition (verbal information + approach‐avoidance training)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Combined condition (approach‐avoidance training + verbal information)
Number of subjects: 160
Study: 24174625

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 219

Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 219
Study: 21341958

Group type: EXPERIMENTAL
Intervention: Audio HIV/AIDS prevention intervention
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (n = 210)
Number of subjects: 210
Study: 18539340

Group type: EXPERIMENTAL
Intervention: Titrated RUL ECT at 2.25 times initial seizure threshold
Number of subjects: 72

Group type: COMPARATOR
Intervention: RUL ECT at a fixed dose of 403 mC
Number of subjects: 72
Study: 17950161

Group type: EXPERIMENTAL
Intervention: Drug and Alcohol Testing (DAT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Deferred Policy
Number of subjects: 11
Study: 15528176

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 45
Study: 11436683

Group type: EXPERIMENTAL
Intervention: Infectious mononucleosis patients
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 42
Study: 9895420

Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonvegetarians
Number of subjects: 38
Study: 7823232

Group type: EXPERIMENTAL
Intervention: Experimental group (physicians received reports summarizing patients' responses)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Control group (physicians received no report)
Number of subjects: 497
Study: 2828412

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (0.5 micrograms daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (1 microgram daily) in a hypoparathyroid patient
Number of subjects: 8
Study: 31541942

Group type: EXPERIMENTAL
Intervention: Chlorogenic acid for injection (CAFI) administered intramuscularly
Number of subjects: 0
Study: 29710125

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening (with and without additional fecal blood testing)
Number of subjects: 98678
Study: 26957044

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying and long-lasting insecticidal nets (not specified dosage or duration)
Number of subjects: 5309
Study: 25039678

Group type: EXPERIMENTAL
Intervention: Kangaroo care with maternal singing
Number of subjects: 86

Group type: COMPARATOR
Intervention: Kangaroo care without maternal singing
Number of subjects: 86
Study: 22367645

Group type: EXPERIMENTAL
Intervention: Trastuzumab exposure during pregnancy (group 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Trastuzumab exposure >3 months after last dose (group 2)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No prior exposure to trastuzumab (group 3)
Number of subjects: 70
Study: 20543266

Group type: EXPERIMENTAL
Intervention: VR and Mobile group with biofeedback (VRMB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VR and Mobile group without biofeedback (VRM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting list group (WL)
Number of subjects: 20
Study: 18031745

Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hyoscine‐N‐butylbromide
Number of subjects: 150

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 150
Study: 15927302

Group type: EXPERIMENTAL
Intervention: Squire's Quest! intervention (10-session psychoeducational multimedia game)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Squire's Quest! intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 26
Study: 14979427

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11801931

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.15-1.0 mg/kg; maximum dose 8-25 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9439409

Group type: EXPERIMENTAL
Intervention: Catheter-valve
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard drainage system
Number of subjects: 100
Study: 7694306

Group type: EXPERIMENTAL
Intervention: risperidone 2‐20 mg daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: haloperidol 2‐20 mg daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 62
Study: 3123607

Group type: EXPERIMENTAL
Intervention: R-(-)-deprenyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of levodopa with deprenyl
Number of subjects: 30
Study: 29689116

Group type: EXPERIMENTAL
Intervention: Furosemide administration
Number of subjects: 3228

Group type: EXPERIMENTAL
Intervention: Furosemide bolus(es) as a preventive measure
Number of subjects: 3228

Group type: COMPARATOR
Intervention: Control group (any comparator)
Number of subjects: 3228
Study: 25856220

Group type: EXPERIMENTAL
Intervention: Probiotic group received a daily capsule containing 10(8) CFUs of Lactobacillus casei 01 for 8 weeks.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group received identical capsules containing maltodextrin for 8 weeks.
Number of subjects: 46
Study: 26215206

Group type: EXPERIMENTAL
Intervention: High stroke volume variation group (maintaining 10‐20% of stroke volume variation)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (maintaining < 10% stroke volume variation)
Number of subjects: 78
Study: 23902783

Group type: EXPERIMENTAL
Intervention: Variety of vegetables (cucumber, sweet pepper, tomato)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Variety of fruit (apple, peach, pineapple)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Single type of vegetables (cucumber, sweet pepper, or tomato)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Single type of fruit (apple, peach, or pineapple)
Number of subjects: 61
Study: 20171055

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (DHA and EPA)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 18266548

Group type: EXPERIMENTAL
Intervention: Caffeine-containing supplement (200 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 16507156

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dopexamine-norepinephrine
Number of subjects: 22
Study: 12763515

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational trials of HRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trials of HRT
Number of subjects: 0
Study: 10890612

Group type: EXPERIMENTAL
Intervention: Small Intestinal (SI) feeding
Number of subjects: 44

Group type: COMPARATOR
Intervention: Gastric (G) feeding
Number of subjects: 44
Study: 8885254

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31375619

Group type: EXPERIMENTAL
Intervention: paediatric Goal Management Training (pGMT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: psychoeducative control intervention (paediatric Brain Health Workshop)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: pGMT
Number of subjects: 80
Study: 30672178

Group type: EXPERIMENTAL
Intervention: Needle-knife therapy combined with moxa stick pressure moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine (12 mg of betahistine mesylate, twice a day, and 75 mg of diclofenac sodium once daily)
Number of subjects: 60
Study: 27377821

Group type: EXPERIMENTAL
Intervention: Nongenital tender point tenderness examination
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fibromyalgia (diagnosed by tender point tenderness)
Number of subjects: 92
Study: 24150782

Group type: EXPERIMENTAL
Intervention: Probiotics supplementation (45 billion CFU of Lactobacillus, Bifidobacterium and Streptococcus strains)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Number of subjects: 10
Study: 22386383

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) with concurrent phlebectomies
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ultrasound‐guided foam sclerotherapy (UGFS)
Number of subjects: 100
Study: 18647300

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 2614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Dapoxetine (30 mg and 60 mg combined)
Number of subjects: 2614
Study: 16949445

Group type: EXPERIMENTAL
Intervention: Visual field end points
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Optic disc end points
Number of subjects: 152
Study: 12589283

Group type: EXPERIMENTAL
Intervention: Daily Gel (Karigel‐N, 5,000 ppm for 4 minutes daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Weekly Varnish (Duraflor, 22,600 ppm weekly)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Weekly Gel (Karigel‐N for 4 minutes weekly)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (washed with deionized/distilled water)
Number of subjects: 80
Study: 10794478

Group type: EXPERIMENTAL
Intervention: Ibuprofen 300 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 9532631

Group type: EXPERIMENTAL
Intervention: Flavoured wavers made from flour and water
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Regional testing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Whole mouth testing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Wavers
Number of subjects: 100
Study: 8468768

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) at levels of 0, 2, 4, 5, 6, 8, 10, 12, 14, 15, and 20 cm H2O
Number of subjects: 10
Study: 3520177

Group type: EXPERIMENTAL
Intervention: Computerized feedback on prescription charges
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0